Changes in use of acute and preventive medications for migraine after erenumab initiation over 12 months: A United States retrospective cohort study

• DOI: 10.1111/head.14820
• Publication Date: 2024-09-09T10:03:05Z
• Authors: Jasjit K. Multani; Robert Urman; Andrew S. Park; Karminder Gill; Fiston Vuvu; Kainan Sun; Leah B. Patel; Karen M. Stockl; Kevin Hawkins; Christopher Rhyne; Mark E. Bensink
• Keywords: Discontinuation

Abstract Objective To assess changes in real‐world use of acute and preventive medications for migraine over a 12‐month follow‐up period the United States following initiation anti‐calcitonin gene‐related peptide (CGRP) pathway monoclonal antibody (mAb) erenumab. Background Early assessments after erenumab have been limited to 6 months follow‐up. Methods This retrospective cohort study used data from IQVIA open‐source longitudinal prescription (LRx) medical (Dx) claims databases. Adult patients with an initial claim (index date) between May 2018 April 2020 were identified. Results Among 201,176 who met inclusion criteria, mean (standard deviation [SD]) age was 47.5 (13.8) years 85.6% ( n = 172,153) female. Most one or more (88.4%; 177,795) traditional (86.1%; 173,225) during pre‐index period. Adherence (proportion days covered [PDC] ≥0.80) 40.2% 80,927) overall (SD) PDC 0.60 (0.34). all patients, 70.0% 140,809) discontinued After accounting 24.7% 49,720) restarted erenumab, discontinuation without reinitiation observed 45.3% 91,089) total patients. Switching different anti‐CGRP mAb 13.1% 26,446) 177,795 medication class, 86.5% 153,788) had post‐index same 56.7% (87,134/153,788) them class Similarly, among 173,225 67.7% 117,274) 46.7% (54,790/117,274) Conclusions In this long‐term study, we both post‐erenumab initiation.